Treatment of intractable neurogenic pain with carbamazepine.
Sixteen patients with previously intractable neurogenic pain were treated with carbamazepine (CBZ) for a period of six weeks. CBZ initial daily dosage of 400 mg was increased by a similar amount every second week to a maximum of 1,200 mg. Single dose kinetic studies prior to initiating CBZ therapy showed that these patients metabolised the drug similarly to healthy controls. Side effects, including rash (3) and ataxia (3), necessitated discontinuation of treatment in six patients. A further three patients withdrew because of lack of effect. Of the seven patients who completed the protocol, five showed a significant fall in pain score at all dosage increments with a maximum effect at the highest dose (p less than 0.01). In the seven patients for whom data was available at all three CBZ dosages, there was a significant correlation between sedation scores and CBZ concentrations (p less than 0.005). CBZ may be of value in the management of chronic neurogenic pain. Further controlled studies are indicated.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001917:Brachial Plexus / Q000293:injuries; D002220:Carbamazepine / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006566:Herpesviridae Infections / Q000150:complications; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000150:complications / Q000209:etiology; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology; D059348:Peripheral Nerve Injuries
D002220:Carbamazepine